Abstract: Applicants have used microarrays, gene expression profiling, and gene silencing methods to identify and provide a plurality of ‘validated’ virus-induced cellular gene sequences (e.g., HMG20B, HRH1, NP and c-YES (src family kinases)) and pathways useful as therapeutic targets for modulation of viral-mediated cellular effects. Particular embodiments provide therapeutic compositions, and methods for modulation of viral infection, replication, maturation, progression, or other virally-related conditions or diseases, comprising inhibition of virally-induced gene sequences and gene products. Additional embodiments provide screening assays for compounds useful to modulate viral infection, replication, maturation or progression, or viral-related conditions or diseases. Further embodiments provide diagnostic and/or prognostic assays for viral infection, replication, maturation or progression. Preferably, the viruses all selected from the group consisting of retroviruses (e.g.

Abstract: Aspects of the present invention use gene expression profiling, and gene silencing methods to identify and provide a plurality of ‘validated’ KSHV-induced cellular gene sequences and pathways useful as targets for modulation of KSHV-mediated effects on cellular proliferation and phenotype (e.g., cancer) associated with latent and lytic phases of the Kaposi's sarcoma-associated herpesvirus (KSHV; Human herpesvirus 8; HHV8) life cycle. Particular embodiments provide therapeutic compositions, and methods for modulation and treatment of KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype, comprising inhibition of KSHV-induced gene sequences or products thereof. Additional embodiments provide screening assays for compounds useful to modulate KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype. Further embodiments provide diagnostic and/or prognostic assays for KSHV infection or related conditions.

Abstract: The present invention uses gene expression profiling, and gene silencing methods to identify and provide a plurality of ‘validated’ KSHV-induced cellular gene sequences and pathways useful as targets for modulation of KSHV-mediated effects on cellular proliferation and phenotype (e.g., cancer) associated with latent and lytic phases of the Kaposi's sarcoma-associated herpesvirus (KSHV; Human herpesvirus 8; HHV8) life cycle. Particular embodiments provide therapeutic compositions, and methods for modulation of KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype, comprising inhibition of KSHV-induced gene sequences. Additional embodiments provide screening assays for compounds useful to modulate KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype. Further embodiments provide diagnostic and/or prognostic assays for KSHV infection.

Abstract: The present invention utilizes nucleic acid microarray technology to identify changes in the host endothelial cell transcription pattern that occurs during the latent and lytic phase of the KSHV life cycle. The production or activity of some genes up regulated during the lytic cycle were subsequently inhibited, and two such targets were shown to have a role in expression of late viral genes. Using this combined approach we have identified cellular pathways previously unknown to be important for KSHV infection, and present evidence for the efficiency of the novel antiviral approaches thus discovered. In addition, the present invention identifies a wide variety of endothelial cells genes and pathways that are involved in a variety of endothelial cell-mediated activity, including angiogenesis and transformation.

Abstract: The present invention utilizes nucleic acid microarray technology to identify changes in the host endothelial cell transcription pattern that occurs during the latent and lytic phase of the KSHV life cycle. The production or activity of some genes up regulated during the lytic cycle were subsequently inhibited, and two such targets were shown to have a role in expression of late viral genes. Using this combined approach we have identified cellular pathways previously unknown to be important for KSHV infection, and present evidence for the efficiency of the novel antiviral approaches thus discovered. In addition, the present invention identifies a wide variety of endothelial cells genes and pathways that are involved in a variety of endothelial cell-mediated activity, including angiogenesis and transformation.

Abstract: The present invention provides methods of latent virus reactivation in monocyte-derived macrophages through allogeneic stimulation of peripheral blood mononuclear cells (“PBMC”), methods of culturing virus, and cultures of virally permissive monocyte-derived macrophages.

Abstract: The present invention provides methods of latent virus reactivation in monocyte-derived macrophages through allogeneic stimulation of peripheral blood mononuclear cells (“PBMC”), methods of culturing virus, and cultures of virally permissive monocyte-derived macrophages.